Tirabrutinib for the treatment of relapsed or refractory primary central nervous system lymphoma: Efficacy and safety from the phase II PROSPECT study Meeting Abstract


Authors: Nayak, L.; Grommes, C.; Kallam, A.; Peereboom, D. M.; Ambady, P.; Mendez, J. S.; Aregawi, D. G.; Sumrall, A. L.; Omuro, A. M. P.; Iwamoto, F.; Dietrich, J.; Umemura, Y.; Munker, R.; Chukwueke, U. N.; Schaff, L.; Prados, S.; Takazawa, A.; Aoi, A.; Batchelor, T.
Abstract Title: Tirabrutinib for the treatment of relapsed or refractory primary central nervous system lymphoma: Efficacy and safety from the phase II PROSPECT study
Meeting Title: J. Clin. Oncol.
Journal Title: Journal of Clinical Oncology
Volume: 43
Issue: 16_SUPPL
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2025-06-01
Language: English
ACCESSION: WOS:001509527500001
DOI: 10.1200/JCO.2025.43.16_suppl.2019
PROVIDER: wos
Notes: Meeting Abstract -- 16_SUPPL -- 2019 -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics